Karyopharm Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Karyopharm Therapeutics

29/10/2024 13:53

* Karyopharm Therapeutics Inc  KPTI.OQ   KPTI.O  is expected
to show a rise in quarterly revenue when it reports  results on
October 31 (estimated) for the period ending September 30 2024
    * The Newton Massachusetts-based  company is expected to
report a
5.4% increase in revenue to $37.958 million from $36.01 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Karyopharm Therapeutics
Inc is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karyopharm
Therapeutics Inc is $4.50​, above​ its last closing price
of $0.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.29       -0.30      0.15      Beat    150.2
 Mar. 31 2024  -0.33       -0.33      -0.32     Beat    4.2
 Dec. 31 2023  -0.31       -0.31      -0.36     Missed  -16.2​
 Sep. 30 2023  -0.28       -0.28      -0.30     Missed  -7.1
 ​​Jun.        -0.35       -0.34      -0.29     Beat    15.3
 30 2023                                                
 Mar. 31 2023  -0.36       -0.37      -0.30     Beat    18.5​
 Dec. 31 2022  -0.35       -0.35      -0.43     Missed  -21.8
 Sep. 30 2022  -0.58       -0.57      -0.45     Beat    20.4
 This summary was machine generated October 29 at 13:53 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)